(123I)FP-CIT SPECT in suspected dementia with Lewy bodies: A longitudinal case study

BMJ Open

Volumn 3, Issue 4, 2013, Pages

  Siepel, Françoise J ^a   Rongve, Arvid ^b   Buter, Tirza C ^a   Beyer, Mona K ^a   Ballard, Clive G ^c   Booij, Jan ^d   Aarsland, Dag ^a,e  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b HAUGESUND HOSPITAL   (Norway)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 123;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLUSTER ANALYSIS; COGNITIVE DEFECT; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HALLUCINATION; HUMAN; LONGITUDINAL STUDY; MALE; NORWAY; PARKINSONISM; REM SLEEP; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VISUAL HALLUCINATION;

EID: 84877715398     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-002642     Document Type: Article

References (42)

1. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-72. (Pubitemid 43970103)
2. Tiraboschi P, Salmon DP, Hansen LA, et al. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain 2006;129(Pt 3):729-35. (Pubitemid 43278234)
3. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24. (Pubitemid 26374873)
4. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6:305-13. (Pubitemid 46367938)
5. Marek K, Jennings D, Seibyl J. Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA study (abstract). Neurology 2005;64(Suppl 1):A274.
6. Cummings JL, Henchcliffe C, Schaier S, et al. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain 2011;134(Pt 11):3146-66.
7. O'Brien JT, McKeith IG, Walker Z, et al. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry 2009;194:34-9.
8. Papathanasiou ND, Boutsiadis A, Dickson J, et al. Diagnostic accuracy of 123I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. Parkinsonism Relat Disord 2012;18:225-9.
9. Aarsland D, Rongve A, Nore SP, et al. Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. Dement Geriatr Cogn Disord 2008;26:445-52.
10. Walker MP, Ayre GA, Cummings JL, et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000;177:252-6.
11. Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004;62:181-7. (Pubitemid 38167122)
12. Boeve BF, Ferman TJ, Silber MH, et al. Validation of a questionnaire for the diagnosis of REM sleep behavior disorder. Neurology 2002;58(Suppl 3):A509.
13. Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 2005;66:633-7. (Pubitemid 40733707)
14. Rongve A, Bronnick K, Ballard C, et al. Core and suggestive symptoms of dementia with Lewy bodies cluster in persons with mild dementia. Dement Geriatr Cogn Disord 2010;29:317-24.
15. Booij J, Hemelaar TG, Speelman JD, et al. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by (123I]FPCIT SPECT. J Nucl Med 1999;40:753-61. (Pubitemid 29210748)
16. Darcourt J, Booij J, Tatsch K, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging 2009;37:443-50.
17. Lebedev AV, Beyer MK, Fritze F, et al. Cortical changes associated with depression in Alzheimer's disease: an MRI surface-based morphometric study (abstract). Eur Psychiatry 2012;27:792.
18. Scheltens P, Barkhof F, Leys D, et al. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 1993;114:7-12. (Pubitemid 23025201)
19. Tolosa E, Borght TV, Moreno E, et al. Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord 2007;22:2346-51. (Pubitemid 351155979)
20. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(Pt 5):2283-301.
21. Ponsen MM, Stoffers D, Booij J, et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004;56:173-81. (Pubitemid 39037913)
22. Ballard CG, Aarsland D, McKeith I, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002;59:1714-20. (Pubitemid 35424452)
23. Braak H, Bohl JR, Muller CM, et al. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 2006;21:2042-51. (Pubitemid 46140410)
24. Halliday GM, McCann H. The progression of pathology in Parkinson's disease. Ann N Y Acad Sci 2010;1184:188-95.
25. Colloby SJ, McParland S, O'Brien JT, et al. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. Brain 2012;135(9):2798-808.
26. Kemp PM, Holmes C. Imaging in dementia with Lewy bodies: a review. Nucl Med Commun 2007;28:511-19. (Pubitemid 46848642)
27. Ballard CG, Jacoby R, Del Ser T, et al. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies. Am J Psychiatry 2004;161:843-9. (Pubitemid 38625337)
28. Duda JE, Giasson BI, Mabon ME, et al. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 2002;52:205-10. (Pubitemid 34810601)
29. Starkstein SE, Merello M, Brockman S, et al. Apathy predicts more severe parkinsonism in Alzheimer's disease. Am J Geriatr Psychiatry 2009;17:291-8.
30. Benitez-Rivero S, Marin-Oyaga VA, Garcia-Solis D, et al. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;84:122-9.
31. Morgan S, Kemp P, Booij J, et al. Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J Neurol Neurosurg Psychiatry 2012;83:1063-70.
32. Lopez-Sendon JL, Mena MA, De Yebenes JG. Drug-induced parkinsonism in the elderly: incidence, management and prevention. Drugs Aging 2012;29:105-18.
33. Diaz-Corrales FJ, Sanz-Viedma S, Garcia-Solis D, et al. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease. Eur J Nucl Med Mol Imaging 2010;37:556-64.
34. Booij J, Kemp P. Dopamine transporter imaging with ((123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging 2008;35:424-38.
35. Nikolaus S, Antke C, Kley K, et al. Pretreatment with haloperidol reduces (123)I-FP-CIT binding to the dopamine transporter in the rat striatum: an in vivo imaging study with a dedicated small-animal SPECT camera. J Nucl Med 2009;50:1147-52.
36. Lavalaye J, Knol RJ, De Bruin K, et al. (123I)FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication. Eur J Nucl Med 2000;27:346-9. (Pubitemid 30167707)
37. Schillaci O, Pierantozzi M, Filippi L, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with(123)I-FP-CIT in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging 2005;32:1452-6. (Pubitemid 41746850)
38. Knol RJ, De Bruin K, Van Eck-Smit BL, et al. No significant effects of single intravenous, single oral and subchronic oral administration of acetylcholinesterase inhibitors on striatal (123I)FP-CIT binding in rats. Eur J Nucl Med Mol Imaging 2008;35:598-604. (Pubitemid 351661675)
39. Booij J, De Jong J, De Bruin K, et al. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med 2007;48:359-66. (Pubitemid 47604917)
40. Ziebell M, Holm-Hansen S, Thomsen G, et al. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. J Nucl Med 2010;51:1885-91.
41. Bjoerke-Bertheussen J, Ehrt U, Rongve A, et al. Neuropsychiatric symptoms in mild dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord 2012;34:1-6.
42. Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med 2011;12:445-53.